期刊文献+

氨基多糖对RANKL诱导的RAW264.7向破骨细胞样细胞分化的抑制作用观察 被引量:1

Observation of GAGs inhibiting the osteoclastogenesis of RAW264.7 in presence of RANKL
下载PDF
导出
摘要 目的探讨氨基多糖(GAGs)对核因子κB受体活化因子配体(RANKL)诱导的RAW264.7向破骨细胞分化的影响。方法采用RANKL单独诱导RAW264.7细胞(对照组),分别采用不同浓度肝素、高分子量透明质酸(HA)、硫酸软骨素(CS)C联合RANKL诱导RAW264.7分化(分别为肝素组、HA组、CSC组)。细胞培养第3、5、7、8天采用抗酒石酸酸性磷酸酶染色法(TRAP)检测破骨细胞样细胞并计数;ELISA法检测第8天各组培养液上清中抗酒石酸酸性磷酸酶5b(TRAP5b)含量。结果与对照组比较,诱导第3、5、7、8天,破骨样细胞数均明显减少(P<0.05);其中肝素组随浓度的增大而减少(P<0.05)。第8天培养液中TRAP5b含量与细胞计数结果相符。结论氨基多糖对RANKL诱导下RAW264.7向破骨细胞样细胞的分化具有抑制作用;肝素的作用具有剂量依赖性。 Objective To investigate the effects of glycosaminoglycan (GAGs) on the osteoclastogenesis of macro- phage cell line RAW264.7 in presence of receptor activator of nuclear factor-kappa B ligand (RANKL). Methods RAW264.7 was induced by RANKL alone in control group. Different concentration gradients of heparin, hyaluronic acid (HA) and chondroitin sulfate C(CS) combined with RANKL were used in heparin, HA and CS group. Tartrate resistant acid phosphatase(TRAP) staining was used to evaluate the numbers of osteoclast-like cells in 3,5,7,8 days. The quantities of TRAPSb in the medium were detected by ELISA. Results The osteoclast-like cell numbers in the experimental groups decreased compared to the control groups in 3, 5, 7, 8 days (P 〈 0.05). The osteoclast-like cell numbers decreased with the increasing of concentration gradients of heparin (P 〈 0. 05 ). TRAPSb quantities in medium were the same to the count results in day 8. Conclusion GAGs can inhibit osteoclastogenesis of RAW264.7 cell line in presence of RANKL. The in- hibition of heparin is in dose-dependent manner.
出处 《山东医药》 CAS 2012年第31期20-22,共3页 Shandong Medical Journal
关键词 氨基多糖 RAW264.7 核因子ΚB受体活化因子配体 抗酒石酸酸性磷酸酶染色 glycosaminoglycan RAW264.7 receptor activator of nuclear factor-kappa B ligand tartrate resistant acid phosphatase staining
  • 相关文献

参考文献11

  • 1Gandhi NS, Mancera RL. The structure of glycosaminoglycans and their interactions with proteins[J]. Chem Biol Drug Des, 2008,72 (6) :455-482.
  • 2Petitou M, Herauh JP, Bernat A, et al. Synthesis of thrombin- inhibiting heparin mimetics without side effects[J]. Nature, 1999,398 (6726) :417422.
  • 3Hulett MD, Freeman C, Hamdorf B J, et al. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis [J]. Nat Med, 1999,5(7) :803-809.
  • 4Walton K J, Duncan JM, Deschamps P, et al. Heparin acts synergistically with interleukin-11 to induce STA33 activation and in vitro osteoclast formation [ J ]. Blood, 2002,100 ( 7 ) : 2530-2536.
  • 5赵宁宁,林久祥,陈智滨,刘妍.正畸保持期龈沟液骨保护素/核因子kappa B受体活化因子配体水平对牙槽骨改建状态的意义[J].北京大学学报(医学版),2012,44(1):108-112. 被引量:2
  • 6Zhang P, Wu Y, Jiang Z, et al. Osteogenic response of mesenchymal stem cells to continuous mechanical strain is dependent on ERK1/2-Runx2 signaling[J]. Int J Mol Med, 2012,29(6) :1083- 1089.
  • 7Chowdhury MH, Hamada C, Dempster DW. Effects of heparin on osteoclast activity[J]. J Bone Miner Res, 1992,7(7) :771-777.
  • 8Ariyoshi W, Takahashi T, Kanno T, et al. Heparin inhibits osteoclastic differentiation and function [ J ]. J Cell Biochem, 2008,103 (6) :1707-1717.
  • 9Shinmyouzu K, Takahashi T, Ariyoshi W, et al. Dermatan sulfate inhibits osteoclast formation by binding to receptor activator of NF- kappa B ligand [ J ]. Biochem Biophys Res Commun, 2007,354 (2) :447-452.
  • 10Chang E J, Kim H J, Ha J, et al. Hyaluronan inhibits osteoclast differentiation via Toll-like receptor 4 [J]. J Cell Sci, 2006,120 (Pt 1 ) : 166-176.

二级参考文献8

共引文献1

同被引文献29

  • 1Fumiyo I, Riko N, Takuma M, et al. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest. 2004;114(4):475-484.
  • 2Retornaz F, Duque G. Osteoporosis in the elderly. Presse Med. 2006;35(10 Pt 2):1547-1556.
  • 3Edwards JR, Weivoda MM. Osteoclasts: malefactors of disease and targets for treatment. Discov Med. 2012;13(70):201-210.
  • 4Maeda SS,Lazaretti-Castro M. An overview on the treatment of postmenopausal osteoporosis. Arq Bras Endocrinol Metabol. 2014;58(2):162-171.
  • 5Kwak HB, Kim JY, Kim K J, et al. Risedronate Directly Inhibits Osteoclast Differentiation and Inflammatory Bone Loss. Biol Pharm Bull. 2009;32(7):1193-1198.
  • 6Kim H J, Zhang K, Zhang L, et al. The Src family kinase, Lyn, suppresses osteoclastogenesis in vitro and in vivo. Proc Natl Acad Sci U S A. 2009;106(7):2325-2330.
  • 7Kim K, Kim JH, Lee J, et al. Nuclear factor of activated T cells cl induces osteoclast-associated receptor gene expression during tumornecrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J Biol Chem. 2005; 280(42 ):35209-35216.
  • 8Horowitz MC, Xi Y, Wilson K, et al, Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev. 2001 ;12(1 ):9-18.
  • 9Halleen JM, Tiitinen SL, Ylipahkala H, et at. Tartrate resistant acid phosphatase 5b(TRACP 5b) a marker of bone resorption Clin Lab. 2006;52(9/10):499-509.
  • 10Rissanen JP, Suominen MI, Peng Z, et al. Secreted tartrate-resistant acid phosphatase 5b is a Marker of osteoclast number in human osteoclast cultures and the rat ovarieetomy model. Caleff Tissue Int. 2008;82(2):108-115.

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部